Archimedes Pharma, which has submitted an NDA for its lead product, PecFent fentanyl nasal spray, announced that it anticipates creating as many as 75 new jobs at its new US headquarters in Bedminster, NJ. The company’s main headquarters are in Reading, UK. Read the company’s press release.
Archimedes to open US headquarters in New Jersey
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
